My last essay ended on a high note. General Biotechnologies had locked in funding to start animal trials of Nivien Therapeutics for treatment-resistant cancer and we’d just scored a win at the Rice Business Plan Competition in Houston.

We took first place in our cohort at RBPC.

Principal at RA Capital, on the boards of 7 biotech companies. Founder/CEO of Nivien Therapeutics. Australian-American. 50 countries and counting.

Principal at RA Capital, on the boards of 7 biotech companies. Founder/CEO of Nivien Therapeutics. Australian-American. 50 countries and counting.